Krsnaa Diagnost. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹240 Cr +31.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
KD

Krsnaa Diagnost.

Q1 FY26

Krsnaa Diagnostics Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹176Cr
+8% YoY
+0.6% QoQ
Net profit
₹20Cr
+11.1% YoY
−4.8% QoQ
Margin
29%
+3 pp YoY
−2 pp QoQ
Price₹562
Market cap₹1.9K Cr
P/E19.2

The short version

Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns. EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.

From Krsnaa Diagnost.'s Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns.
  • Management expects volume and revenue growth to be higher than industry averages going forward.
  • Rajasthan PPP contract rollout underway; full implementation of labs and collection centers expected over 6-9 months, with meaningful revenue from next financial year.
  • Retail diagnostics (RPL) rapidly scaling, contributing ~6% of revenues; expected to grow to 5%-8% by FY '26.
  • Retail business targeted to breakeven by FY '26 with 18%-20% revenue contribution anticipated within 1-1.5 years.
  • Expansion in Maharashtra, Punjab, Assam, and Odisha, leveraging PPP backbone to accelerate retail growth.

2 more points from Krsnaa Diagnost.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Rajasthan PPP project: CAPEX increased to around INR 200-250 crores, involving 42 mother labs, 135 satellite labs, and 1,335 collection centers; rollout phased over next 6-9 months, with revenues starting FY '27. - Maharashtra radiology expansion: Completion of major portion (75%) of 73 centers including CT and MRI by end of Q3. - Equipment acquisition strategy: Preference for purchase over lease to align with tender requirements and strategic needs. - Funding strategy: Combination of internal accruals, debt at efficient cost, leasing/reagent rental models being explored for Rajasthan CAPEX. Overall, investments focus on scaling PPP contracts and retail diagnostic infrastructure, targeting profitable growth.

Fundraising & Capital Structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company is actively pursuing tenders but it is too early to provide specific details about the current tender pipeline.
  • As tenders come up, the company will share details accordingly.
  • The Rajasthan PPP contract is a major new order with CAPEX estimated around INR 200-250 crores, expected to start generating revenues from FY 2027.
  • The Rajasthan project includes 42 mother labs, 135 satellite labs, and over 1,300 collection centers targeted for full operations by FY 2026.
  • There is ongoing implementation and expansion of radiology and pathology centers in Maharashtra, Madhya Pradesh, and Uttar Pradesh within the current order book.

2 more points from Krsnaa Diagnost.'s call on order book

Create a free account to keep reading this call

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Krsnaa Diagnost. Q1 FY26 results — key figures

Krsnaa Diagnost. Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue176163+8%175+0.6%
Operating profit (EBITDA)5043+16.3%53-5.7%
Operating margin29%26%+3 pp31%-2 pp
Profit before tax2624+8.3%29-10.3%
Net profit (PAT)2018+11.1%21-4.8%
EPS (₹)6.035.63+7.1%6.53-7.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aster DM Quality (Q1 FY26)

    Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…

  • Dr Agarwal's Hea (Q1 FY26)

    70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…

  • Syngene International (Q1 FY26)

    Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…

  • Yatharth Hospital & Trauma Care Services (Q1 FY26)

    International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Krsnaa Diagnost. Q1 FY26 results?

Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects like BMC, but expected to improve with initiatives and awareness campaigns. EBITDA grew by 19% YoY to INR 524 million with a 120 bps margin expansion to 27%.

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

Rajasthan PPP project: CAPEX increased to around INR 200-250 crores, involving 42 mother labs, 135 satellite labs, and 1,335 collection centers; rollout phased over next 6-9 months, with revenues starting FY '27.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.